IL33 and stage 5 chronic kidney disease: Interestingly, although the ST2/IL-33 signaling pathway seems to be involved in various inflammatory processes [63,64,65,66], the aforementioned study by Alam et al. did not find a statistically significant association of the plasma levels of sST2 with the progression of CKD to end-stage renal disease (ESRD) [60].